Pediatric myelofibrosis: WHO 2024 update on myeloproliferative neoplasms calling?


Journal

Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624

Informations de publication

Date de publication:
05 2020
Historique:
received: 10 09 2019
accepted: 08 02 2020
pubmed: 7 3 2020
medline: 14 7 2020
entrez: 6 3 2020
Statut: ppublish

Résumé

Pediatric myelofibrosis is a rare entity with the largest reported series of 19 cases. We describe here the clinicopathological spectrum and outcomes of 15 cases of pediatric myelofibrosis. Case files of myelofibrosis of patients less than 18 years were retrieved from January 2016 to January 2019, and patients with idiopathic myelofibrosis after exhaustive work-up were studied. Their clinicopathological profiles were studied and then followed up for resolution and malignant transformation. Of the 15 cases of idiopathic myelofibrosis, transfusion-dependent anemia (14/15) was most common presentation. Only one patient showed leukoerythroblastosis with dacryocytes. Myeloid hyperplasia was seen in 13 of 15 patients and megakaryocytic hyperplasia in 10 patients. Dysmegakaryopoiesis was seen in 8 of 15 patients, and only three had small loose megakaryocytic clustering. None showed hyperchromatic megakaryocytes, intrasinusoidal hematopoiesis, or osteosclerosis. One patient with trisomy 8 tested positive for JAK2V617F. Bone marrow biopsy was hypercellular in 13, and 8 had world health organization (WHO) MF-3 fibrosis. None of the patients developed malignancy, one had spontaneous resolution, and one patient required allogenic stem cell transplant. Pediatric myelofibrosis is a distinct entity from primary myelofibrosis in adults and merits mention in the WHO manual as a distinct entity.

Identifiants

pubmed: 32134181
doi: 10.1002/pbc.28232
doi:

Substances chimiques

Neoplasm Proteins 0
JAK2 protein, human EC 2.7.10.2
Janus Kinase 2 EC 2.7.10.2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e28232

Informations de copyright

© 2020 Wiley Periodicals, Inc.

Références

Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood. 2008;112:45-52.
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405.
DeLario MR, Sheehan AM, Ataya R, et al. Clinical, histopathologic, and genetic features of pediatric primary myelofibrosis-an entity different from adults. Am J Hematol. 2012;87(5):461-464.
An W, Wan Y, Guo Y, et al. CALR mutation screening in pediatric primary myelofibrosis. Pediatr Blood Cancer. 2014;61(12):2256-2262.
Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90:1128-1132.
Stepensky P, Saada A, Cowan M, et al. The Thr224Asn mutation in the VPS45 gene is associated with the congenital neutropenia and primary myelofibrosis of infancy. Blood. 2013;121:5078-5087.
Vilboux T, Lev A, Malicdan MC, et al. A congenital neutrophil defect syndrome associated with mutations in VPS45. N Engl J Med. 2013;369(1):54-65.
Hofmann I. Myeloproliferative neoplasms in children. J Hematopathol. 2015;8:143-157.
Sheikha A. Fatal familial infantile myelofibrosis. J Pediatr Hematol Oncol. 2004;26:164-168.
Sieff CA, Malleson P. Familial myelofibrosis. Arch Dis Child. 1980;55:888-893.
Noor-Fadzilah Z, Leong CF, Sabariah MN, Cheong SK. Childhood idiopathic myelofibrosis: a case report and review of literature. Malaysian J Pathol. 2009;31(2):129-132.
Domm J, Calder C, Manes B, Crossno C, Correa H, Frangoul H. Unrelated stem cell transplant for infantile idiopathic myelofibrosis. Pediatr Blood Cancer. 2009;52:893-895.

Auteurs

Priyanka Mishra (P)

Department of Hematology, All India Institute of Medical Sciences (AIIMS), New Delhi, India.

Rohan Halder (R)

Department of Hematology, All India Institute of Medical Sciences (AIIMS), New Delhi, India.

Mukul Aggarwal (M)

Department of Hematology, All India Institute of Medical Sciences (AIIMS), New Delhi, India.

Tulika Seth (T)

Department of Hematology, All India Institute of Medical Sciences (AIIMS), New Delhi, India.

Manoranjan Mahapatra (M)

Department of Hematology, All India Institute of Medical Sciences (AIIMS), New Delhi, India.

Hara Prasad Pati (HP)

Department of Hematology, All India Institute of Medical Sciences (AIIMS), New Delhi, India.

Renu Saxena (R)

Department of Hematology, All India Institute of Medical Sciences (AIIMS), New Delhi, India.

Seema Tyagi (S)

Department of Hematology, All India Institute of Medical Sciences (AIIMS), New Delhi, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH